- Breast Cancer
- Prostate Cancer
- Colorectal Cancer
- Cervical Cancer
- Liver Cancer
- Lung Cancer
- Blood Cancer
- Kidney Cancer
- Others
Oncology Molecular Diagnostics Market size was valued at USD 3.63 billion in 2022 and expected to reach a value of USD 8.32 billion by 2029, growing at a CAGR of 12.6% from 2023-29 . The global market provides a detailed overview of the Oncology Molecular Diagnostics market and that can be segmented by type, product, test location, and technology. By type, The Oncology Molecular Diagnostics market has been segmented into Breast Cancer, Prostate Cancer, Colorectal Cancer, Cervical Cancer, Liver Cancer, Lung Cancer, Blood Cancer, Kidney Cancer, and Others. The Brest cancer segment is likely to be the largest and fastest-growing segment in terms of type. Based on product the Oncology Molecular Diagnostics Market is segmented into Instruments, Reagents, and Others. Among these, the reagents segment is expected to have the fastest-growing market during the forecast period 2023-2029. Based on the test location, the Oncology Molecular Diagnostics Market is segmented into Clinics and Other Establishments, Others. The clinic segment accounts for the largest share in 2022.
Oncology Molecular Diagnostics Market Key Development:
- In February 2020, Danaher (Cepheid) announced a collaboration with Sherlock Biosciences to explore the innovative, ground-breaking molecular diagnostic test development intended for oncology and infectious diseases deploying CRISPR technology.
Oncology Molecular Diagnostics Market Summary
Study Period
2024-2030
Base Year
2023
CAGR
12.6%
Largest Market
North-America
Fastest Growing Market
Asia-Pacific
Oncology Molecular Diagnostics Market Dynamics
Increase in the prevalence of cancers such as breast cancer in women and prostate cancer is men is the major factor anticipated to burgeon the oncology molecular diagnostics market over the forecast years. Moreover, rise in R&D for the development of point of care diagnostic test kits, government initiatives for the cancer screening programs, and the launch of advanced test kits are immense boost to the market over the forecast timeframe.
Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Oncology Molecular Diagnostics Market Segmentation
By Type
By Product Type
- Instruments
- Reagents
- Others
By Technology
- PCR
- In Situ Hybridization
- Isothermal Nucleic Acid Amplification Technology (INAAT)
- Chips & Microarrays
- Chips & Microarrays
- Sequencing
- Transcription Mediated Amplification
- Others
Frequently Asked Questions
The Oncology Molecular Diagnostics Market is projected to expand at a CAGR of 12.6% during the forecast period.
The major players in the global oncology molecular diagnostics market are Abbott Laboratories, Bayer Healthcare AG, Beckman Coulter, Inc., Becton, Dickinson and Company, Cepheid, Inc., Danaher Corporation, Hologic, Inc., Leica Biosystems Inc., Qiagen NV, Roche Diagnostics (Schweiz) AG, Siemens Healthineers, Sysmex Corporation
Asia-Pacific is the fastest-growing region for Oncology Molecular Diagnostics Market
| 1. Executive Summary |
| 2. Global Oncology Molecular Diagnostics Market Introduction |
| 2.1. Global Oncology Molecular Diagnostics Market - Taxonomy |
| 2.2. Global Oncology Molecular Diagnostics Market -Definitions |
| 2.2.1. By Type |
| 2.2.2. By Product |
| 2.2.3. By Test Location |
| 2.2.4. By Technology |
| 2.2.5. By Region |
| 3. Global Oncology Molecular Diagnostics Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Oncology Molecular Diagnostics Market Dynamic Factors - Impact Analysis |
| 3.6. Global Oncology Molecular Diagnostics Market - Competition Landscape |
| 3.7. Epidemiology Data |
| 4. Global Oncology Molecular Diagnostics Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 |
| 4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Oncology Molecular Diagnostics Market, By Type, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1. Breast Cancer |
| 5.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Prostate Cancer |
| 5.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Colorectal Cancer |
| 5.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Cervical Cancer |
| 5.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Liver Cancer |
| 5.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Lung Cancer |
| 5.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Blood Cancer |
| 5.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 5.8. Kidney Cancer |
| 5.8.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.8.3. Market Opportunity Analysis |
| 5.9. Others |
| 5.9.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 5.9.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.9.3. Market Opportunity Analysis |
| 6. Global Oncology Molecular Diagnostics Market, By Product, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1. Instruments |
| 6.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Reagents |
| 6.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 6.3. Others |
| 6.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 6.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.3.3. Market Opportunity Analysis |
| 7. Global Oncology Molecular Diagnostics Market, By Test Location, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1. Clinics and Other Establishments |
| 7.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. Others |
| 7.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 8. Global Oncology Molecular Diagnostics Market, By Technology, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.1. PCR |
| 8.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.1.3. Market Opportunity Analysis |
| 8.2. In Situ Hybridization |
| 8.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.2.3. Market Opportunity Analysis |
| 8.3. Isothermal Nucleic Acid Amplification Technology (INAAT) |
| 8.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.3.3. Market Opportunity Analysis |
| 8.4. Chips & Microarrays |
| 8.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.4.3. Market Opportunity Analysis |
| 8.5. Mass Spectroscopy |
| 8.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.5.3. Market Opportunity Analysis |
| 8.6. Sequencing |
| 8.6.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.6.3. Market Opportunity Analysis |
| 8.7. Transcription Mediated Amplification |
| 8.7.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.7.3. Market Opportunity Analysis |
| 8.8. Others |
| 8.8.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 8.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 8.8.3. Market Opportunity Analysis |
| 9. Global Oncology Molecular Diagnostics Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.1. North America |
| 9.1.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.1.3. Market Opportunity Analysis |
| 9.2. Europe |
| 9.2.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.2.3. Market Opportunity Analysis |
| 9.3. Asia-Pacific |
| 9.3.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.3.3. Market Opportunity Analysis |
| 9.4. Latin America |
| 9.4.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.4.3. Market Opportunity Analysis |
| 9.5. Middle East and Africa |
| 9.5.1. Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 9.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 9.5.3. Market Opportunity Analysis |
| 9.6. Global Oncology Molecular Diagnostics Market - Opportunity Analysis Index, By Type, By Resin, By Application, and Region, 2023 - 2029 |
| 10. North America Oncology Molecular Diagnostics Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 10.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Breast cancer |
| 10.1.2. Prostate cancer |
| 10.1.3. Colorectal cancer |
| 10.1.4. Cervical cancer |
| 10.1.5. Liver cancer |
| 10.1.6. Lung cancer |
| 10.1.7. Blood cancer |
| 10.1.8. Kidney cancer |
| 10.1.9. Others |
| 10.2. Product Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.2.1. Instruments |
| 10.2.2. Reagents |
| 10.2.3. Others |
| 10.3. Test Location Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Clinics and other establishments |
| 10.3.2. Point of Care |
| 10.4. Technology Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 10.4.1. PCR |
| 10.4.1.1. Multiplex |
| 10.4.1.2. Others |
| 10.4.2. In Situ Hybridization |
| 10.4.3. Isothermal Nucleic Acid Amplification Technology (INAAT) |
| 10.4.4. Chips and microarrays |
| 10.4.5. Mass spectrometry |
| 10.4.6. Sequencing |
| 10.4.7. Transcription Mediated Amplification |
| 10.4.8. Others |
| 10.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.5.1. U.S. |
| 10.5.2. Canada |
| 10.6. North America Oncology Molecular Diagnostics Market - Opportunity Analysis Index, By Type, Product, Test Location, Technology, And Country, 2023 - 2029 |
| 10.7. North America Oncology Molecular Diagnostics Market Dynamics - Trends |
| 11. Europe Oncology Molecular Diagnostics Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 11.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Breast cancer |
| 11.1.2. Prostate cancer |
| 11.1.3. Colorectal cancer |
| 11.1.4. Cervical cancer |
| 11.1.5. Liver cancer |
| 11.1.6. Lung cancer |
| 11.1.7. Blood cancer |
| 11.1.8. Kidney cancer |
| 11.1.9. Others |
| 11.2. Product Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.2.1. Instruments |
| 11.2.2. Reagents |
| 11.2.3. Others |
| 11.3. Test Location Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Clinics and other establishments |
| 11.3.2. Point of Care |
| 11.4. Technology Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 11.4.1. PCR |
| 11.4.1.1. Multiplex |
| 11.4.1.2. Others |
| 11.4.2. In Situ Hybridization |
| 11.4.3. Isothermal Nucleic Acid Amplification Technology (INAAT) |
| 11.4.4. Chips and microarrays |
| 11.4.5. Mass spectrometry |
| 11.4.6. Sequencing |
| 11.4.7. Transcription Mediated Amplification |
| 11.4.8. Others |
| 11.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.5.1. Germany |
| 11.5.2. UK |
| 11.5.3. France |
| 11.5.4. Spain |
| 11.5.5. Italy |
| 11.5.6. Russia |
| 11.5.7. Poland |
| 11.5.8. Rest of Europe |
| 11.6. Europe Oncology Molecular Diagnostics Market - Opportunity Analysis Index, By Type, Product, Test Location, Technology, And Country, 2023 - 2029 |
| 11.7. Europe Oncology Molecular Diagnostics Market Dynamics - Trends |
| 12. Asia-Pacific Oncology Molecular Diagnostics Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 12.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 12.1.1. Breast cancer |
| 12.1.2. Prostate cancer |
| 12.1.3. Colorectal cancer |
| 12.1.4. Cervical cancer |
| 12.1.5. Liver cancer |
| 12.1.6. Lung cancer |
| 12.1.7. Blood cancer |
| 12.1.8. Kidney cancer |
| 12.1.9. Others |
| 12.2. Product Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.2.1. Instruments |
| 12.2.2. Reagents |
| 12.2.3. Others |
| 12.3. Test Location Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.3.1. Clinics and other establishments |
| 12.3.2. Point of Care |
| 12.4. Technology Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 12.4.1. PCR |
| 12.4.1.1. Multiplex |
| 12.4.1.2. Others |
| 12.4.2. In Situ Hybridization |
| 12.4.3. Isothermal Nucleic Acid Amplification Technology (INAAT) |
| 12.4.4. Chips and microarrays |
| 12.4.5. Mass spectrometry |
| 12.4.6. Sequencing |
| 12.4.7. Transcription Mediated Amplification |
| 12.4.8. Others |
| 12.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 12.5.1. Japan |
| 12.5.2. China |
| 12.5.3. India |
| 12.5.4. ASEAN |
| 12.5.5. Australia & New Zealand |
| 12.5.6. Rest of Asia-Pacific |
| 12.6. Asia-Pacific Oncology Molecular Diagnostics Market - Opportunity Analysis Index, By Type, Product, Test Location, Technology, And Country, 2023 - 2029 |
| 12.7. Asia-Pacific Oncology Molecular Diagnostics Market Dynamics - Trends |
| 13. Latin America Oncology Molecular Diagnostics Market Analysis, 2018 - 2022 and Forecast, 2020 - 2026 |
| 13.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 13.1.1. Breast cancer |
| 13.1.2. Prostate cancer |
| 13.1.3. Colorectal cancer |
| 13.1.4. Cervical cancer |
| 13.1.5. Liver cancer |
| 13.1.6. Lung cancer |
| 13.1.7. Blood cancer |
| 13.1.8. Kidney cancer |
| 13.1.9. Others |
| 13.2. Product Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.2.1. Instruments |
| 13.2.2. Reagents |
| 13.2.3. Others |
| 13.3. Test Location Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.3.1. Clinics and other establishments |
| 13.3.2. Point of Care |
| 13.4. Technology Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 13.4.1. PCR |
| 13.4.1.1. Multiplex |
| 13.4.1.2. Others |
| 13.4.2. In Situ Hybridization |
| 13.4.3. Isothermal Nucleic Acid Amplification Technology (INAAT) |
| 13.4.4. Chips and microarrays |
| 13.4.5. Mass spectrometry |
| 13.4.6. Sequencing |
| 13.4.7. Transcription Mediated Amplification |
| 13.4.8. Others |
| 13.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 13.5.1. Brazil |
| 13.5.2. Mexico |
| 13.5.3. Argentina |
| 13.5.4. Rest of Latin America |
| 13.6. Latin America Oncology Molecular Diagnostics Market - Opportunity Analysis Index, By Type, Product, Test Location, Technology, And Country, 2023 - 2029 |
| 13.7. Latin America Oncology Molecular Diagnostics Market Dynamics - Trends |
| 14. Middle East and Africa Oncology Molecular Diagnostics Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn) |
| 14.1. Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 14.1.1. Breast cancer |
| 14.1.2. Prostate cancer |
| 14.1.3. Colorectal cancer |
| 14.1.4. Cervical cancer |
| 14.1.5. Liver cancer |
| 14.1.6. Lung cancer |
| 14.1.7. Blood cancer |
| 14.1.8. Kidney cancer |
| 14.1.9. Others |
| 14.2. Product Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 14.2.1. Instruments |
| 14.2.2. Reagents |
| 14.2.3. Others |
| 14.3. Test Location Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 14.3.1. Clinics and other establishments |
| 14.3.2. Point of Care |
| 14.4. Technology Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%) |
| 14.4.1. PCR |
| 14.4.1.1. Multiplex |
| 14.4.1.2. Others |
| 14.4.2. In Situ Hybridization |
| 14.4.3. Isothermal Nucleic Acid Amplification Technology (INAAT) |
| 14.4.4. Chips and microarrays |
| 14.4.5. Mass spectrometry |
| 14.4.6. Sequencing |
| 14.4.7. Transcription Mediated Amplification |
| 14.4.8. Others |
| 14.5. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 14.5.1. Gulf Cooperation Council (GCC) Countries |
| 14.5.2. Israel |
| 14.5.3. South Africa |
| 14.5.4. Rest of MEA |
| 14.6. MEA Oncology Molecular Diagnostics Market - Opportunity Analysis Index, By Type, Product, Test Location, Technology, And Country, 2023 - 2029 |
| 14.7. MEA Oncology Molecular Diagnostics Market Dynamics - Trends |
| 15. Competition Landscape |
| 15.1. Strategic Dashboard of Top Market Players |
| 15.1.1. Company Profiles (Introduction, Financial Analysis, Key Developments, Strategies, and SWOT Analysis) |
| 15.1.2. Abbott Laboratories |
| 15.1.3. Bayer Healthcare AG |
| 15.1.4. Beckman Coulter, Inc. |
| 15.1.5. Becton, Dickinson and Company |
| 15.1.6. Cepheid, Inc. |
| 15.1.7. Danaher Corporation |
| 15.1.8. Hologic, Inc. |
| 15.1.9. Leica Biosystems Inc. |
| 15.1.10. Qiagen NV |
| 15.1.11. Roche Diagnostics (Schweiz) AG |
| 15.1.12. Siemens Healthineers |
| 15.1.13. Sysmex Corporation |
| 16. Research Methodology |
| 17. Key Assumptions and Acronyms |
- Abbott Laboratories
- Bayer Healthcare AG
- Beckman Coulter, Inc.
- Becton, Dickinson and Company
- Cepheid, Inc.
- Danaher Corporation
- Hologic, Inc.
- Leica Biosystems Inc.
- Qiagen NV
- Roche Diagnostics (Schweiz) AG
- Siemens Healthineers
- Sysmex Corporation